Article
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer
2025-07-19
Abstract excerpt
<h4>Summary</h4> Treatment options and diagnostic outlook for men with advanced, therapy resistant prostate cancer (PCa) are extremely poor; this is primarily due to the common lack of durable response to androgen receptor (AR) targeted therapies and phenotypic transdifferentiation into a particularly lethal subtype known as neuroendocrine prostate cancer (NEPC). In this study, we mechanistically determine that S...
Topics
Open a Topic to create a Post that cites this publication.
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Estrogen and related hormone effects
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Prostate Cancer Treatment and Research
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
Identifiers and source
- Literature Corpus work
- 5611efe8-a91a-564a-abb4-088b70963769
- DOI
- 10.1101/2025.07.18.664790
